NASDAQ:CALT Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis $40.00 0.00 (0.00%) As of 05/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CALT alerts:Sign Up Key Stats Today's Range$40.00▼$40.0050-Day Range$40.00▼$40.0052-Week Range$15.25▼$43.00VolumeN/AAverage Volume10,339 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calliditas Therapeutics AB (publ) is a Sweden-based biopharmaceutical company dedicated to the development and commercialization of novel therapies for rare immunologic and renal diseases. The company’s scientific focus centers on targeting the underlying causes of immune-mediated conditions with oral and biologic formulations. By leveraging proprietary drug delivery technologies, Calliditas aims to bring differentiated treatments to patients who currently have limited therapeutic options. The company’s lead product, Tarpeyo® (budesonide) delayed-release capsules, received U.S. Food and Drug Administration (FDA) approval in October 2021 for the treatment of adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. Calliditas holds exclusive commercial rights for Tarpeyo in North America and several other territories, and it continues to pursue regulatory submissions and market access efforts in Europe and select international markets. In parallel, the company is advancing a preclinical pipeline of novel immunomodulatory compounds aimed at expanding its rare disease portfolio. Founded in 2004 and headquartered in Stockholm, Calliditas Therapeutics maintains operations across Europe and North America, supported by a corporate office in Boston to oversee U.S. commercialization activities. The company is publicly traded on the Nasdaq Stockholm exchange as well as on the Nasdaq Global Select Market in the United States under the ticker symbol CALT. Calliditas is led by an experienced management team with backgrounds in biopharmaceutical research, regulatory affairs and commercial strategy, positioning the company to execute its growth plans in the global rare disease arena.AI Generated. May Contain Errors. Read More Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALT Stock News HeadlinesCalliditas Therapeutics’ Setanaxib Study: A Potential Game-Changer for Alport SyndromeAugust 14, 2025 | msn.comCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.May 8 at 1:00 AM | Porter & Company (Ad)Calliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comSee More Headlines CALT Stock Analysis - Frequently Asked Questions How have CALT shares performed this year? Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of the year. Since then, CALT stock has increased by 0.0% and is now trading at $40.0001. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. The firm had revenue of $52.36 million for the quarter, compared to analyst estimates of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%. Read the conference call transcript. When did Calliditas Therapeutics AB (publ) IPO? Calliditas Therapeutics AB (publ) (CALT) raised $81 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 4,153,385 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager. How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Target (TGT) and Company Calendar Last Earnings8/13/2024Today5/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALT CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees180Year Founded2004Profitability EPS (Trailing Twelve Months)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.96 million Net Margins-30.18% Pretax Margin-29.40% Return on Equity-212.04% Return on Assets-27.96% Debt Debt-to-Equity Ratio9.44 Current Ratio2.69 Quick Ratio2.59 Sales & Book Value Annual Sales$1.60 billion Price / Sales0.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book37.74Miscellaneous Outstanding Shares29,790,000Free Float29,135,000Market Cap$1.19 billion OptionableNo Data Beta1.77 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CALT) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredNobody's Asking Where The SpaceX Money Comes FromWhen SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
